顺铂联合吉西他滨与联合多西紫杉醇治疗晚期非小细胞肺癌疗效观察

摘要

Objective To observe the therapeutic effects,survival rates and adverse reactions of cisplatin combined with gemcitabine or docetaxel in treatment of non-small cell lung cancer ( NSCLC ). Methods 60 patients with NSCLC were randomly divided into two groups, 30 patients in each groups. The 30 patients in GP group were treated by cisplatin combined with gemcitabine, however, the other 30 patients in TP group were treated by cisplatin combined with docetaxel. The effective rates, survival rates and adverse reactions were observed and were statistically analyzed. Results There were no significant differences in the therapeutic effects between GP group and TP group( 53.3％ vs 56.7％, P ＞ 0.05 ). The l-year survival rate was 50％ in GP group, which was 46.7％ in TP group, there was no significant difference between two groups( P ＞0. 05). The most common adverse reactions were neutropenia, next hemoglobin decrease and damage of renal function in beth groups. The incidence of baldness in TP group was significantiy higher than that of GP group( P ＜0.05) ,and the incidence of thrombecytopenia in GP group was significantly higher than that of TP group( P ＜ 0.05 ). There were no significant differences in the other adverse reactions between two groups ( P ＞ 0. 05 ). Conclusion The protocol of gemcitabine combined with cisplatin or paclitaxel is effective in treating NSCLC, which is worthy of being popularized in clinic.%目的 探讨顺铂联合吉西他滨与联合多西紫杉醇治疗晚期非小细胞肺癌(NSCLC)的疗效、生存率及不良反应.方法 我院60例NSCLC患者随机分为2组,每组30例,1组给予顺铂联合吉西他滨方案(GP组),另1组给予顺铂联合多西紫杉醇方案(TP组),观察2组有效率、生存率及不良反应.结果 GP组的PR为53.3%,TP组的PR为56.7%,2组比较差异无统计学意义(P＞0.05);GP组一年生存率为50%,TP组为46.7%,2组比较差异无统计学意义(P＞0.05);2组最常见的不良反应是白细胞减少,其次为血红蛋白减少和肾功能的损害,TP组脱发不良反应明显高于GP组,GP组血小板减少的不良反应明显高于TP组(P<0.05),余不良反应2组比较差异均无统计学意义(P＞0.05).结论 吉西他滨联合顺铂方案和紫杉醇联合顺铂方案对于治疗晚期NSCLC疗效确切,值得临床推广应用.